Hae-Young Kim

Publications

1. Short- and Long-Term Risk of Meningitis Following Pediatric Endoscopic Transsphenoidal Surgery. Laryngoscope. 2025 Mar 24. View Abstract
2. Dysphonia in Preschool-Aged Children: Efficacy of Voice Therapy. J Voice. 2025 Feb 28. View Abstract
3. Predictors of Thyroglossal Duct Cyst Recurrence and Complications Following Sistrunk Procedure. Laryngoscope. 2025 Feb 20. View Abstract
4. Predictors of Posttransplant Lymphoproliferative Disease in Pediatric Patients. Laryngoscope. 2025 Jan 30. View Abstract
5. Incidence, Clearance, and Persistence of Penile High-Risk Human Papillomavirus Among Rwandan Men Who Have Sex With Men. J Infect Dis. 2024 Oct 16; 230(4):e964-e970. View Abstract
6. Incidence of Hearing Loss in Patients With Neurofibromatosis Type 1 at a Tertiary Care Pediatric Hospital. Pediatr Neurol. 2024 Oct; 159:35-40. View Abstract
7. Coprevalence and associations of diabetes mellitus and hypertension among people living with HIV/AIDS in Cameroon. AIDS Res Ther. 2024 06 01; 21(1):36. View Abstract
8. Comparison of AmpFire and MY09/11 assays for HPV genotyping in anogenital specimen of Rwandan men who have sex with men. Heliyon. 2023 May; 9(5):e16016. View Abstract
9. Association Between Time to Antiretroviral Therapy and Loss to Care Among Newly Diagnosed Rwandan People Living with Human Immunodeficiency Virus. AIDS Res Hum Retroviruses. 2023 05; 39(5):253-261. View Abstract
10. Human cortical interneurons optimized for grafting specifically integrate, abort seizures, and display prolonged efficacy without over-inhibition. Neuron. 2023 03 15; 111(6):807-823.e7. View Abstract
11. Exploring barriers to abortion access: Medical students' intentions, attitudes and exposure to abortion. Sex Reprod Healthc. 2022 Dec; 34:100790. View Abstract
12. Agreement between Xpert and AmpFire tests for high-risk human papillomavirus among HIV-positive women in Rwanda. Afr J Lab Med. 2022; 11(1):1827. View Abstract
13. Impact of schizophrenia GWAS loci converge onto distinct pathways in cortical interneurons vs glutamatergic neurons during development. Mol Psychiatry. 2022 10; 27(10):4218-4233. View Abstract
14. Decision-To-Delivery Interval in Obese Patients Undergoing Emergent Cesarean Birth. Obstet Gynecol Res. 2022; 5(3):219-224. View Abstract
15. Awareness and Willingness to Use HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Rwanda: A Cross-Sectional Descriptive Survey. J Assoc Nurses AIDS Care. 2021 Nov-Dec 01; 32(6):693-700. View Abstract
16. Hypertension among people living with HIV/AIDS in Cameroon: A cross-sectional analysis from Central Africa International Epidemiology Databases to Evaluate AIDS. PLoS One. 2021; 16(7):e0253742. View Abstract
17. Trends in demographic and clinical characteristics and initiation of antiretroviral therapy among adult patients enrolling in HIV care in the Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) 2004 to 2018. J Int AIDS Soc. 2021 06; 24(6):e25672. View Abstract
18. Correction: iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. Mol Psychiatry. 2020 Nov; 25(11):3103-3104. View Abstract
19. Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia. Nat Neurosci. 2020 11; 23(11):1352-1364. View Abstract
20. Factors Impacting Physical Therapy Utilization for Patients With Nonspecific Low Back Pain: Retrospective Analysis of a Clinical Data Set. Phys Ther. 2020 08 31; 100(9):1502-1515. View Abstract
21. Anogenital Human Papillomavirus and HIV Infection in Rwandan Men Who Have Sex With Men. J Acquir Immune Defic Syndr. 2020 08 15; 84(5):463-469. View Abstract
22. Firth Adjustment for Weibull Current-Status Survival Analysis. Communications in Statistics - Theory and Methods. 2020; 49(18):4587-4602. View Abstract
23. iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. Mol Psychiatry. 2020 11; 25(11):2873-2888. View Abstract
24. Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia. Nat Neurosci. 2019 02; 22(2):229-242. View Abstract
25. Community Hospital Experience of Surgical Times and Outcomes in Patients Undergoing Cesarean Deliveries for Non-Reassuring Fetal Tracing: A Retrospective Cohort. Open Journal of Anesthesiology. 2019; 9:203-211. View Abstract
26. An Interval-Censored Proportional Hazards Model. Journal of Data Science. 2018; 16(4):829–856. View Abstract
27. Preoperative Urodynamic Parameters (Valsalva Leak Point Pressure and Maximum Urethral Closure Pressure), Urinary Collagen and Plasma Vitamin D Levels as Predictors of Mid Urethral Sling Surgery Outcome. J Urol. 2016 Sep; 196(3):819-23. View Abstract
28. Changes in urinary bisphenol A concentrations associated with placement of dental composite restorations in children and adolescents. J Am Dent Assoc. 2016 08; 147(8):620-30. View Abstract
29. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail. 2016 Mar; 9(3):e001937. View Abstract
30. Effects of a worksite tobacco control intervention in India: the Mumbai worksite tobacco control study, a cluster-randomised trial. Tob Control. 2017 03; 26(2):210-216. View Abstract
31. Power and sample size calculations for interval-censored survival analysis. Stat Med. 2016 Apr 15; 35(8):1390-400. View Abstract
32. Change in Overactive Bladder Symptoms After Surgery for Stress Urinary Incontinence in Women. Obstet Gynecol. 2015 Aug; 126(2):423-430. View Abstract
33. Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. Br J Haematol. 2015 Jun; 169(6):887-98. View Abstract
34. Missing data frequency and correlates in two randomized surgical trials for urinary incontinence in women. Int Urogynecol J. 2015 Aug; 26(8):1155-9. View Abstract
35. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circ Heart Fail. 2015 Mar; 8(2):268-77. View Abstract
36. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014 Jan; 62(1):16-24. View Abstract
37. Findings of universal cystoscopy at incontinence surgery and their sequelae. Am J Obstet Gynecol. 2014 May; 210(5):480.e1-8. View Abstract
38. The minimum important difference for the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form in women with stress urinary incontinence. Neurourol Urodyn. 2015 Feb; 34(2):183-7. View Abstract
39. Inflammatory and tissue remodeling urinary biomarkers before and after mid urethral sling surgery for stress urinary incontinence. J Urol. 2014 Mar; 191(3):703-9. View Abstract
40. Repeat post-op voiding trials: an inconvenient correlate with success. Neurourol Urodyn. 2014 Nov; 33(8):1225-8. View Abstract
41. Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. Am J Hematol. 2013 Sep; 88(9):771-3. View Abstract
42. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. 2013 May 20; 15:38. View Abstract
43. Longitudinal changes in high-density lipoprotein cholesterol and cardiovascular events in older adults. Clin Endocrinol (Oxf). 2014 May; 80(5):662-70. View Abstract
44. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica. 2013 Sep; 98(9):1359-67. View Abstract
45. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013 Apr; 10(2):319-31. View Abstract
46. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013 Mar; 6(2):184-92. View Abstract
47. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion. 2013 Apr; 53(4):704-9. View Abstract
48. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012 Mar 22; 119(12):2746-53. View Abstract
49. Inpatient management of sickle cell pain: a 'snapshot' of current practice. Am J Hematol. 2012 Mar; 87(3):333-6. View Abstract
50. Estimating Agreement Coefficient from Sample Survey Data. Survey Methodology. 2012; 38(1):63-72. View Abstract
51. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat. 2012 Jun; 19(6):404-13. View Abstract
52. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov; 54(5):1527-37. View Abstract
53. Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. Am J Hematol. 2011 Dec; 86(12):E70-3. View Abstract
54. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug; 54(2):434-42. View Abstract
55. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood. 2011 Oct 06; 118(14):3794-802. View Abstract
56. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405. View Abstract
57. A pilot study of subcutaneous decitabine in ß-thalassemia intermedia. Blood. 2011 Sep 08; 118(10):2708-11. View Abstract
58. Renal dysfunction in patients with thalassaemia. Br J Haematol. 2011 Apr; 153(1):111-7. View Abstract
59. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol. 2011 Apr; 153(1):121-8. View Abstract
60. Optimal Configuration of a Square Array Group Testing Algorithm. Commun Stat Theory Methods. 2011 Jan 01; 40(3):436-448. View Abstract
61. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar; 140(3):840-9; quiz e12. View Abstract
62. Education and employment status of children and adults with thalassemia in North America. Pediatr Blood Cancer. 2010 Oct; 55(4):678-83. View Abstract
63. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3):833-44. View Abstract
64. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010 Apr; 31(7):719-34. View Abstract
65. Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications. Am J Hematol. 2009 Nov; 84(11):759-61. View Abstract
66. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb; 138(2):493-502. View Abstract
67. Power and sample size calculations for current status survival analysis. Stat Med. 2009 Jul 10; 28(15):1999-2011. View Abstract
68. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun; 49(6):1828-37. View Abstract
69. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009 Aug; 137(2):549-57. View Abstract
70. Three-dimensional array-based group testing algorithms. Biometrics. 2009 Sep; 65(3):903-10. View Abstract
71. Modeling survival data with informative cluster size. Stat Med. 2008 Feb 20; 27(4):543-55. View Abstract
72. Weighting condom use data to account for nonignorable cluster size. Ann Epidemiol. 2007 Aug; 17(8):603-7. View Abstract
73. Comparison of group testing algorithms for case identification in the presence of test error. Biometrics. 2007 Dec; 63(4):1152-63. View Abstract
74. Analytic, Computational, and Approximate Forms for Ratios of Noncentral and Central Gaussian Quadratic Forms. J Comput Graph Stat. 2006 Jun 01; 15(2):443-459. View Abstract
75. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment Pharmacol Ther. 2006 Jun 01; 23(11):1667-75. View Abstract
76. Stability of irritable bowel syndrome using a Rome II-based classification. Aliment Pharmacol Ther. 2006 Jan 01; 23(1):197-205. View Abstract
77. Sample-size calculations for studies with correlated ordinal outcomes. Stat Med. 2005 Oct 15; 24(19):2977-87. View Abstract
78. Partner counseling and referral services to identify persons with undiagnosed HIV--North Carolina, 2001. MMWR Morb Mortal Wkly Rep. 2003 Dec 05; 52(48):1181-4. View Abstract
Show All Publications Show Fewer Publications